NRF2

Scientific explanation

NRF2/KEAP1 controls antioxidant and detoxification . KEAP1 or NFE2L2 mutations in lung and other cancers stabilize NRF2 and can confer therapy resilience.

Cancers where relevant

Lung cancer Non-small-cell lung cancer KRAS-driven NSCLC Kidney / renal cell carcinoma

Compounds that intersect this pathway

N-acetylcysteine

Cysteine donor replenishing glutathione. Redox buffering can be protective or, in some models, support tumour antioxidant capacity. Dual-edged; not an antineoplastic.

Evidence in mapped cancers: In Vitro · Mechanistically Plausible · Hypothesis-Generating

Sulforaphane

Isothiocyanate that can activate NRF2 via KEAP1 modification and has epigenetic HDAC-related reports in models. Chemoprevention hypotheses exceed proven oncology treatment.

Evidence in mapped cancers: In Vitro · In Vivo · Mechanistically Plausible

Convergence partners

Other pathways that co-occur with NRF2 on mapped adjunct records: Oxidative stress, Ferroptosis.

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.